StreetAlpha.app
Home › Stocks › RAPP

Rapport Therapeutics, Inc. (RAPP)

Healthcare
$23.16
▼ −1.82%
LAST CLOSE · NOV 20

Rapport Therapeutics develops small molecule drugs for neurological and psychiatric disorders, led by a candidate for focal onset seizures. It last closed at $23.16 on Nov 20, down 1.82% on the day. The next earnings report for RAPP is expected around Tue, Mar 9, 2027. For the quarter ended Sep 2026, RAPP reported EPS of -$0.84 on revenue of $0. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months RAPP insiders bought $22.0M of stock on the open market and sold $46.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is RAPP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RAPP.

Key Stats

Last 12 months
Results
Net income
−$150.5M
EPS (diluted)
−$3.17
Free cash flow
−$121.2M
Valuation
Market cap
$1.4B
59.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$74.8M
At Sep 30
Shareholder equity
$391.2M
Shares outstanding
59.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$34.8M−$34.8MFY2023FY2024: −$78.3M−$78.3MFY2024FY2025: −$111.5M−$111.5MFY2025

From RAPP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 9
Estimated date · Time not announced
Reported EPS
-$0.84
Quarter ended Sep 2026
Year ago EPS
-$0.71
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.12Dec '24Mar 2025: -$0.68Mar '25Jun 2025: -$0.75Jun '25Sep 2025: -$0.71Sep '25Dec 2025: -$0.71Dec '25Mar 2026: -$0.42Mar '26Jun 2026: -$1.19Jun '26Sep 2026: -$0.84Sep '26Latest -$0.84
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Mar 2026: $20.0MMar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How RAPP moved after its last 8 reports
Average move the session after a report ±4.1%
Oct 30, 2026After the close+0.3%
Aug 5, 2026Time not announced+0.6%
May 7, 2026Time not announced+7.7%
Mar 10, 2026Time not announced−3.0%
Nov 6, 2025Time not announced−3.1%
Aug 7, 2025Time not announced+5.5%
May 8, 2025Time not announced+4.2%
Mar 11, 2025Time not announced+8.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RAPPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RAPP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RAPP

Technical Analysis

RAPP · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 8% below its 20 day and 29% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the swing low (Nov 6) at $22.95, and the nearest resistance the Pivot at $23.33.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 8.1%/day
Key levels
$52.9352 week high+128.5%
$37.22100 day average+60.7%
$35.51200 day average+53.3%
$29.8550 day average+28.9%
$26.36Swing high (Nov 4)+13.8%
$24.9520 day average+7.7%
$23.66Pivot R1+2.2%
$23.33Pivot+0.7%
$23.16Last close
$22.95Swing low (Nov 6)−0.9%
$22.83Pivot S1−1.4%
$22.0652 week low−4.7%
Indicators
RSI (14)37.17Weak, oversold below 30Neutral
MACD-1.66Above its signal lineBullish
Stochastic11.3Near the bottom of its rangeOversold
ADX (14)30.8Trending down
Williams %R-94.0Oversold below −80, overbought above −20Oversold
CCI (20)-111.3Oversold below −100, overbought above 100Oversold
Rate of change−5.2%Change over 10 sessionsBearish
ATR (14)$1.87Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RAPP

What happened before

See how RAPP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for RAPPHow many large options trades hit RAPP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RAPP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲90 buying vs 64 selling
  • ▼Held by funds -1.3 pts
  • ▲Funds holding +9
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170161+5.6%
In funds' top 1067−14.3%
Held by funds85.2%86.5%−1.3 pts
New / increased31 / 5926 / 56+9.8%
Reduced / sold out40 / 2446 / 12+10.3%
Put/call ratio2.17––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RAPP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RAPP Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$22.0M7 buys · 7 insiders
Sold$46.7M32 sales · 5 insiders
99% of the selling was under pre-arranged trading plans.
Cluster buy: 7 insiders bought $22.0M between Oct 21 and Oct 28.
2025-12 sold $861K2026-01 sold $513K2026-02 sold $567K2026-03 sold $643K2026-04 sold $18.7M2026-05 sold $17.2M2026-06 sold $743K2026-07 sold $421K2026-08 sold $5.9M2026-09 sold $793K2026-10 bought $22.0M2026-10 sold $208KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 28James HealyDirectorBuy969,480$21.00$20.4M
Oct 23Ramiro SanchezDirectorBuy3,600$27.35$98K
Oct 22John MaraganoreDirectorBuy9,411$26.45$249K
Oct 22Steven M PaulDirectorBuy35,714$27.28$974K
Oct 22Wendy B. YoungDirectorBuy3,789$26.39$100K
Oct 22Paul M SilvaDirectorBuy3,680$27.07$100K
Every insider buy and sale for RAPP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RAPP insider trades →

From SEC Form 4 filings by RAPP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RAPP is in one of them and how their past RAPP trades turned out.

RAPP in the AI portfolios
Loading…

RAPP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RAPP in an article yet. Here's the latest on the wider market.

RAPP in the news

About Rapport Therapeutics

Rapport Therapeutics is a biotechnology company based in Boston, Massachusetts, that develops small molecule drugs for neurological and psychiatric disorders. Its lead candidate, RAP-219, is being studied for focal onset seizures, a form of epilepsy, and is also being evaluated for generalized seizures and bipolar mania. The company is also developing an injectable version of that candidate and earlier-stage programs aimed at chronic pain, migraine, and hearing and balance disorders. Its intended market is patients with these conditions and the physicians who treat them.

Headquarters
Boston, MA